Edward M. Kaye M.D., Director at Stoke Therapeutics, Inc. (STOK), sold 28,271 shares at $30.76 ($879K) on 2025-12-04, disclosed to the SEC on 2025-12-05.
Scheduled sale ($879k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $30.76 | 5,222 | $161K | 18.3% |
| 2 | $30.76 | 5,222 | $161K | 18.3% |
| 3 | $31.32 | 1,231 | $39K | 4.4% |
| 4 | $31.15 | 1,681 | $52K | 6.0% |
| 5 | $31.15 | 1,681 | $52K | 6.0% |
| 6 | $31.33 | 6,367 |
| $199K |
| 22.7% |
| 7 | $31.33 | 6,367 | $199K | 22.7% |
| 8 | $31.85 | 500 | $16K | 1.8% |
| Total | $31.11 avg | 28,271 | $879K | 100% |
| Filing → |
| STOK | SELL | 2025-12-10 | $702K | — | Filing → |
| STOK | SELL | 2025-12-03 | $65K | — | Filing → |
| CYTK | SELL | 2025-12-02 | $3.7M | — | Filing → |